Pharmaceuticals News and Research

RSS

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.

25 Feb 2014

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.

25 Feb 2014

Research roundup: Palliative care and ACOs; employers and Supreme Court case on contraception

In preparation for the new ACO environment, leaders recognized the contribution palliative care can make to health care "value," especially in the care of our sickest (and most expensive) patients ...

24 Feb 2014

Study highlights novel reprogramming method that offers new hope for treating liver failure

The power of regenerative medicine now allows scientists to transform skin cells into cells that closely resemble heart cells, pancreas cells and even neurons. However, a method to generate cells that are fully mature-a crucial prerequisite for life-saving therapies-has proven far more difficult.

24 Feb 2014

Researcher uses computational approach to speed up process of drug discovery

OIST researcher uses a computational approach in identifying proteins that will interact with potential drugs to speed up the process of drug discovery.

24 Feb 2014

UCSF and Samsung partner to accelerate validation of new digital health technologies

Samsung Electronics Co., Ltd., and UC San Francisco (UCSF), one of the world's premier health sciences universities, today announced a partnership to accelerate validation and commercialization of promising new sensors, algorithms, and digital health technologies for preventive health solutions.

24 Feb 2014

Viewpoints: Docs on drugmakers' payrolls; no comparison shopping in health care

Doctors have long gotten small favors from drug makers: pads with logos, a deli tray sent to the office, tickets to sporting events and free drug samples.

23 Feb 2014

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has completed dosing of its Phase 2 clinical trial of GCS-100 for the treatment of chronic kidney disease ("CKD") and has collected the final data for evaluation of the primary endpoint.

23 Feb 2014

Research sheds light on pathological mechanisms that trigger psoriasis lesions

Streptococcal antigens (Streptococcus pyogenes) might be directly involved in the pathological mechanisms that result in the appearance of psoriasis lesions.

21 Feb 2014

Leeds scientists develop high-power quantum cascade terahertz lasers

A paper in the Institution of Engineering and Technology's (IET) journal Electronics Letters reports that the Leeds team has exceeded a 1 Watt output power from a quantum cascade terahertz laser.

21 Feb 2014

Genetic study reveals 11 new genetic signals are associated with blood pressure levels

A large international study analyzing genes in tens of thousands of individuals has discovered 11 new genetic signals associated with blood pressure levels. Ten of those signals are in or very near genes encoding proteins that appear to be likely targets for drugs already in existence or in development.

21 Feb 2014

Impax Laboratories records adjusted net loss of $1.6 million in fourth quarter 2013

Impax Laboratories, Inc. today reported fourth quarter and full year ended December 31, 2013 results.

21 Feb 2014

OrthoTrophix commences TPX-100 Phase 2 clinical study in knee osteoarthritis patients

OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company started a Phase 2 clinical study of its cartilage repair therapeutic agent, TPX-100, with knee osteoarthritis patients in the U.S. The Company also announced that it had successfully closed the second and last tranche of its Series A preferred stock financing.

20 Feb 2014

CAS announces landmark five-year agreement for SciFinder with AstraZeneca

Chemical Abstracts Service, the world's authority for chemical information, announced today a landmark five-year agreement for SciFinder, the choice for chemistry research, with AstraZeneca, a leading biopharmaceutical company specializing in the discovery, development, manufacturing and marketing of prescription medicines. The long-term agreement guarantees AstraZeneca researchers access to the most accurate, comprehensive and current research, available only in SciFinder.

20 Feb 2014

Medicines that mimic body's natural systems can prevent debilitating side effects

Debilitating side effects associated with prescription medication for some of today's most common conditions could be eradicated if they mimicked the body's natural hormone secretion cycles, a new report has said.

20 Feb 2014

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

20 Feb 2014

Pharmaceuticals News and Research

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Research roundup: Palliative care and ACOs; employers and Supreme Court case on contraception

Study highlights novel reprogramming method that offers new hope for treating liver failure

Researcher uses computational approach to speed up process of drug discovery

UCSF and Samsung partner to accelerate validation of new digital health technologies

Viewpoints: Docs on drugmakers' payrolls; no comparison shopping in health care

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

Research sheds light on pathological mechanisms that trigger psoriasis lesions

Leeds scientists develop high-power quantum cascade terahertz lasers

Genetic study reveals 11 new genetic signals are associated with blood pressure levels

Impax Laboratories records adjusted net loss of $1.6 million in fourth quarter 2013

OrthoTrophix commences TPX-100 Phase 2 clinical study in knee osteoarthritis patients

CAS announces landmark five-year agreement for SciFinder with AstraZeneca

Medicines that mimic body's natural systems can prevent debilitating side effects

Lung cancer patients with Del19 mutation benefit most from afatinib

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Study highlights lack of policies or guidelines regarding wheelchairs and seating provision in Ireland

Purdue’s new innovation improves drug therapies by making real-time decisions about treatment options

Jubilant Biosys expands drug discovery alliance with Janssen Pharmaceutica

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence